 |
Insmed Granted Key Composition of Matter Patent Allowance for ARIKACE in Europe
May 14, 2013
|
13.0 KB |
|
| |
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 05/14/13 --
Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat patients battling serious lung diseases in orphan indications that are often life-threatening, today announced that the European Patent Office intends ...
|
|
Insmed to Present at the UBS Global Healthcare Conference
May 13, 2013
|
12.1 KB |
|
| |
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 05/13/13 --
Insmed Incorporated (NASDAQ: INSM) ("Insmed" or the "Company"), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat patients battling serious lung diseases that are often life-threatening, today announced that Will Lewis, President and Chi...
|
|
Insmed to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
May 10, 2013
|
12.1 KB |
|
| |
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 05/10/13 --
Insmed Incorporated (NASDAQ: INSM) ("Insmed" or the "Company"), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat patients battling serious lung diseases that are often life-threatening, today announced that Will Lewis, President and Chi...
|
|
Insmed Reports First Quarter Financial Results
May 7, 2013
|
23.1 KB |
|
| |
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 05/07/13 --
Insmed Incorporated (NASDAQ: INSM), ("Insmed" or the "Company"), a biopharmaceutical company focused on developing and commercializing an inhaled anti-infective to treat patients battling serious lung diseases that are often life-threatening, reported financial results for the three months en...
|
|
Insmed to Host First Quarter 2013 Financial Results Conference Call on Tuesday, May 7, 2013
May 1, 2013
|
12.7 KB |
|
| |
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 05/01/13 --
Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases in orphan indications that are often life-threatening, today announced that the Company will release financial results for t...
|
|
Insmed to Present at the 12th Annual Needham Healthcare Conference
Apr 18, 2013
|
11.5 KB |
|
| |
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 04/18/13 --
Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases in orphan indications that are often life-threatening, today announced Will Lewis, President and Chief Executive Officer of ...
|
|
Insmed Appoints Matthew Pauls as Chief Commercial Officer
Apr 1, 2013
|
14.6 KB |
|
| |
MONMOUTH JUNCTION, NJ -- (Marketwire) -- 04/01/13 --
Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases in orphan indications that are often life-threatening, announces the appointment of Matthew Pauls as Chief Commercial Officer...
|
|
ARIKACE Receives Orphan Drug Designation for Treating Infections Caused by Non-Tuberculous Mycobacteria
Mar 28, 2013
|
12.2 KB |
|
| |
MONMOUTH JUNCTION, NJ -- (Marketwire) -- 03/28/13 --
Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases in orphan indications that are often life-threatening, today announced that ARIKACE®, the Company's Iiposomal amikacin ...
|
|
Insmed to Present at Future Leaders in the Biotech Industry Conference
Mar 27, 2013
|
12.0 KB |
|
| |
MONMOUTH JUNCTION, NJ -- (Marketwire) -- 03/27/13 --
Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases in orphan indications that are often life-threatening, today announced Will Lewis, President and Chief Executive Officer of I...
|
|
Insmed Reports Fourth Quarter and Full Year 2012 Financial Results
Mar 18, 2013
|
24.3 KB |
|
| |
MONMOUTH JUNCTION, NJ -- (Marketwire) -- 03/18/13 --
Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life-threatening, reported financial results for the three and twelve months ended December 31, 2012.
...
|
|
Insmed to Host Fourth Quarter and Full Year 2012 Financial Results Conference Call on Monday, March 18, 2013
Mar 11, 2013
|
13.7 KB |
|
| |
MONMOUTH JUNCTION, NJ -- (Marketwire) -- 03/11/13 --
Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious orphan lung diseases that are often life-threatening, today announced that the Company will release financial results for the three and twe...
|
|
Insmed to Present at Two Upcoming Investor Conferences
Feb 26, 2013
|
12.7 KB |
|
| |
MONMOUTH JUNCTION, NJ -- (Marketwire) -- 02/26/13 --
Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious orphan lung diseases that are often life-threatening, today announced that members of Insmed's management team will be presenting the Compa...
|
|
Insmed to Present at Two Upcoming Healthcare Investor Conferences
Feb 6, 2013
|
12.5 KB |
|
| |
MONMOUTH JUNCTION, NJ -- (Marketwire) -- 02/06/13 --
Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious orphan lung diseases that are often life-threatening, today announced that Will Lewis, President and Chief Executive Officer of Insmed, wil...
|
|
Insmed to Present at 31st Annual J.P. Morgan Healthcare Conference
Dec 13, 2012
|
12.4 KB |
|
| |
MONMOUTH JUNCTION, N.J., Dec. 13, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing and commercializing novel, targeted inhaled therapies for patients with high unmet need who are battling serious orphan lung diseases, today announced that the Company will be participating in the 31st Annu...
|
|
Insmed Announces CLEAR-108 Phase 3 Clinical Study of ARIKACE® in Cystic Fibrosis Patients with Pseudomonas Lung Infections Has Completed Target Enrollment
Nov 13, 2012
|
13.1 KB |
|
| |
MONMOUTH JUNCTION, N.J., Nov. 13, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that the Company's CLinical Evaluation of ARIKACE (CLEAR-108) phase 3 European and Canadian registrational study of ARIKACE® (lipo...
|
|
Insmed To Present At Two Upcoming Investor Conferences
Nov 12, 2012
|
11.8 KB |
|
| |
MONMOUTH JUNCTION, N.J., Nov. 12, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced that Will Lewis, President and Chief Executive Officer, will be presenting a corporate overview at the Lazard Capital Markets 9th Annua...
|
|
Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2012
Nov 7, 2012
|
30.5 KB |
|
| |
MONMOUTH JUNCTION, N.J., Nov. 7, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company dedicated to the development of innovative inhaled pharmaceuticals for the treatment of serious lung infections, today reported results for the third quarter and nine-months ended September 30, 2012.
Key Recent Highlights
...
|
|
Insmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer
Nov 7, 2012
|
13.2 KB |
|
| |
MONMOUTH JUNCTION, N.J., Nov. 7, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced the appointment of Andrew Drechsler to the position of Chief Financial Officer. Mr. Drechsler will assume the role of Principal Financia...
|
|
Insmed to Host 2012 Third Quarter Earnings Conference Call
Oct 24, 2012
|
12.1 KB |
|
| |
MONMOUTH JUNCTION, N.J., Oct. 24, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing novel inhalation therapeutics for patients suffering from serious orphan lung diseases, will host a conference call on Wednesday, November 7th, 2012, at 8:30 AM ET, to discuss its financial results for the ...
|
|
Insmed Announces Pricing of Approximately $26 Million Direct Public Offering
Sep 28, 2012
|
11.2 KB |
|
| |
MONMOUTH JUNCTION, N.J., Sept. 28, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing novel inhalation therapeutics for patients suffering from serious orphan lung diseases, today announced that it has priced a direct public offering of approximately 6.3 million shares of its Common Stock t...
|
|
|
